Posted by Michael Wonder on 08 Jun 2021
Biogen and Eisai launch multiple initiatives to help patients with Alzheimer’s disease access Aduhelm
7 June 2021 - Value based agreements in progress with Cigna and other payers.
Following today’s U.S. FDA accelerated approval of Aduhelm (aducanumab-avwa) as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease by reducing amyloid beta plaques in the brain, Biogen and Eisai announced a range of programs intended to support access for all qualified patients, including traditionally underserved populations.
These initiatives aim to help patients and their families understand the disease, navigate the diagnostic journey, secure culturally competent care and afford treatment.
